Molecular Diagnostics of Neurodegenerative Disorders

Overview

Journal Front Mol Biosci

Specialty Biology

Date 2015 Oct 7

PMID 26442283

Citations 59

Authors

Megha Agrawal

Abhijit Biswas

Affiliations

Soon will be listed here.

Abstract

Molecular diagnostics provide a powerful method to detect and diagnose various neurological diseases such as Alzheimer's and Parkinson's disease. The confirmation of such diagnosis allows early detection and subsequent medical counseling that help specific patients to undergo clinically important drug trials. This provides a medical pathway to have better insight of neurogenesis and eventual cure of the neurodegenerative diseases. In this short review, we present recent advances in molecular diagnostics especially biomarkers and imaging spectroscopy for neurological diseases. We describe advances made in Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic lateral sclerosis (ALS) and Huntington's disease (HD), and finally present a perspective on the future directions to provide a framework for further developments and refinements of molecular diagnostics to combat neurodegenerative disorders.

Citing Articles

Decoding Neurodegeneration: A Review of Molecular Mechanisms and Therapeutic Advances in Alzheimer's, Parkinson's, and ALS.

Toader C, Tataru C, Munteanu O, Serban M, Covache-Busuioc R, Ciurea A Int J Mol Sci. 2024; 25(23.

PMID: 39684324 PMC: 11641752. DOI: 10.3390/ijms252312613.

A comprehensive review of advanced focused ultrasound (FUS) microbubbles-mediated treatment of Alzheimer's disease.

Rouhi N, Chakeri Z, Ghorbani Nejad B, Rahimzadegan M, Khezri M, Kamali H Heliyon. 2024; 10(18):e37533.

PMID: 39309880 PMC: 11416559. DOI: 10.1016/j.heliyon.2024.e37533.

Pharmacological Assessment of Aqueous Ethanolic Extract of Against Haloperidol-Induced Parkinson's Like Symptoms in Animal Model: A Dose-Dependent Study With Mechanistic Approach.

Han J, Hao X, Fatima M, Chauhdary Z, Jamshed A, Abdur Rahman H Dose Response. 2024; 22(3):15593258241282020.

PMID: 39224700 PMC: 11367614. DOI: 10.1177/15593258241282020.

Targeting amyloid proteins for clinical diagnosis of neurodegenerative diseases.

Zhang S, Dong H, Bian J, Li D, Liu C Fundam Res. 2024; 3(4):505-519.

PMID: 38933553 PMC: 11197785. DOI: 10.1016/j.fmre.2022.10.009.

Drug Development for Alzheimer's and Parkinson's Disease: Where Do We Go Now?.

Sequeira L, Benfeito S, Fernandes C, Lima I, Peixoto J, Alves C Pharmaceutics. 2024; 16(6).

PMID: 38931832 PMC: 11206728. DOI: 10.3390/pharmaceutics16060708.

References

Gasser T, Bressman S, Durr A, Higgins J, Klockgether T, Myers R . State of the art review: molecular diagnosis of inherited movement disorders. Movement Disorders Society task force on molecular diagnosis. Mov Disord. 2003; 18(1):3-18. DOI: 10.1002/mds.10338. View

Joyce N, Carter G . Electrodiagnosis in persons with amyotrophic lateral sclerosis. PM R. 2013; 5(5 Suppl):S89-95. PMC: 4590769. DOI: 10.1016/j.pmrj.2013.03.020. View

Weir D, Sturrock A, Leavitt B . Development of biomarkers for Huntington's disease. Lancet Neurol. 2011; 10(6):573-90. DOI: 10.1016/S1474-4422(11)70070-9. View

Gasser T, Dichgans M, Finsterer J, Hausmanowa-Petrusewicz I, Jurkat-Rott K, Klopstock T . EFNS Task Force on Molecular Diagnosis of Neurologic Disorders: guidelines for the molecular diagnosis of inherited neurologic diseases. First of two parts. Eur J Neurol. 2001; 8(4):299-314. DOI: 10.1046/j.1468-1331.2001.00226.x. View

Hu Y, Chopra V, Chopra R, Locascio J, Liao Z, Ding H . Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse. Proc Natl Acad Sci U S A. 2011; 108(41):17141-6. PMC: 3193232. DOI: 10.1073/pnas.1104409108. View

Sjogren M, Andreasen N, Blennow K . Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers. Clin Chim Acta. 2003; 332(1-2):1-10. DOI: 10.1016/s0009-8981(03)00121-9. View

El-Agnaf O, Irvine G . Aggregation and neurotoxicity of alpha-synuclein and related peptides. Biochem Soc Trans. 2002; 30(4):559-65. DOI: 10.1042/bst0300559. View

Rachakonda V, Pan T, Le W . Biomarkers of neurodegenerative disorders: how good are they?. Cell Res. 2004; 14(5):347-58. DOI: 10.1038/sj.cr.7290235. View

Sunderland T, Linker G, Mirza N, Putnam K, Friedman D, Kimmel L . Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA. 2003; 289(16):2094-103. DOI: 10.1001/jama.289.16.2094. View

10.

Lovrecic L, Kastrin A, Kobal J, Pirtosek Z, Krainc D, Peterlin B . Gene expression changes in blood as a putative biomarker for Huntington's disease. Mov Disord. 2009; 24(15):2277-81. DOI: 10.1002/mds.22477. View

11.

Zhai W, Jeong H, Cui L, Krainc D, Tjian R . In vitro analysis of huntingtin-mediated transcriptional repression reveals multiple transcription factor targets. Cell. 2005; 123(7):1241-53. DOI: 10.1016/j.cell.2005.10.030. View

12.

Margis R, Margis R, R M Rieder C . Identification of blood microRNAs associated to Parkinsonĭs disease. J Biotechnol. 2011; 152(3):96-101. DOI: 10.1016/j.jbiotec.2011.01.023. View

13.

Hardy J, Selkoe D . The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002; 297(5580):353-6. DOI: 10.1126/science.1072994. View

14.

. A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Parkinson Study Group. Neurology. 2000; 55(10):1540-7. DOI: 10.1212/wnl.55.10.1540. View

15.

Bonifati V, Rizzu P, van Baren M, Schaap O, Breedveld G, Krieger E . Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2002; 299(5604):256-9. DOI: 10.1126/science.1077209. View

16.

Wild E, Boggio R, Langbehn D, Robertson N, Haider S, Miller J . Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients. J Clin Invest. 2015; 125(5):1979-86. PMC: 4463213. DOI: 10.1172/JCI80743. View

17.

Berezovska O, Ramdya P, Skoch J, Wolfe M, Bacskai B, Hyman B . Amyloid precursor protein associates with a nicastrin-dependent docking site on the presenilin 1-gamma-secretase complex in cells demonstrated by fluorescence lifetime imaging. J Neurosci. 2003; 23(11):4560-6. PMC: 6740808. View

18.

Fergani A, Dupuis L, Jokic N, Larmet Y, de Tapia M, Rene F . Reticulons as markers of neurological diseases: focus on amyotrophic lateral sclerosis. Neurodegener Dis. 2006; 2(3-4):185-94. DOI: 10.1159/000089624. View

19.

Saman S, Kim W, Raya M, Visnick Y, Miro S, Saman S . Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J Biol Chem. 2011; 287(6):3842-9. PMC: 3281682. DOI: 10.1074/jbc.M111.277061. View

20.

Gasser T, Dichgans M, Finsterer J, Hausmanowa-Petrusewicz I, Jurkat-Rott K, Klopstock T . EFNS Task Force on Molecular Diagnosis of Neurologic Disorders: guidelines for the molecular diagnosis of inherited neurologic diseases. Second of two parts. Eur J Neurol. 2001; 8(5):407-24. DOI: 10.1046/j.1468-1331.2001.00228.x. View